Extensive promoter analyses and studies of SNCA mRNA in dopaminergic neurons (DN) showed that genotype-dependent regulatory mechanisms of SNCA expression contribute to the risk of sPD, and a recent study revealed that its expression in brain in vivo is regulated predominantly by intronic enhancers [6–9]. Here, SNCA is linked to Platelet storage pool disease.